Zydus and Torrent ink pact to co-market Saroglitazar for liver diseases

13 Nov 2023 , 10:26 AM

Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited have collaborated on a licensing and supply arrangement to co-market Saroglitazar Mg in India, which is used to treat Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD).

According to a press release, Saroglitazar Magnesium, the country’s sole licensed medicine for NASH and NAFLD, is anticipated to play a crucial role in treating and reducing severe liver illnesses.

Torrent receives semi-exclusive rights to co-market the product as VORXAR under this deal. The original creator, Zydus, will continue to commercialize the medicine under the brand names Lipaglyn and Bilypsa. Torrent will pay Zydus upfront licensing fees as well as milestone payments based on preset milestones.

The drug aroglitazar Mg, which has been approved by India’s Drugs Controller General, is a breakthrough in the treatment of chronic liver disorders such as NASH and NAFLD. It is the first medicine approved in any country for these disorders. There is currently no other licensed medicine in the world for NASH and NAFLD.

Saroglitazar Magnesium is a substantial development in NASH and NAFLD, illness regions with high prevalence and limited clinically supported treatment alternatives.  This will strengthen the company’s gastrointestinal business while also addressing growing unmet patient requirements.

For feedback and suggestions, write to us at [e-mail]